[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2018124033A1 - 脂質粒子組成物および医薬組成物 - Google Patents

脂質粒子組成物および医薬組成物 Download PDF

Info

Publication number
WO2018124033A1
WO2018124033A1 PCT/JP2017/046564 JP2017046564W WO2018124033A1 WO 2018124033 A1 WO2018124033 A1 WO 2018124033A1 JP 2017046564 W JP2017046564 W JP 2017046564W WO 2018124033 A1 WO2018124033 A1 WO 2018124033A1
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
lipid particle
panobinostat
particle composition
composition according
Prior art date
Application number
PCT/JP2017/046564
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
雄大 吉野
隼人 小椋
幹永 森
泰輔 遠藤
健太郎 沼尻
律子 堀
Original Assignee
富士フイルム株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 富士フイルム株式会社 filed Critical 富士フイルム株式会社
Priority to CN201780080668.3A priority Critical patent/CN110114068A/zh
Priority to ES17888488T priority patent/ES2968358T3/es
Priority to JP2018559499A priority patent/JPWO2018124033A1/ja
Priority to EP17888488.8A priority patent/EP3560492B1/en
Publication of WO2018124033A1 publication Critical patent/WO2018124033A1/ja
Priority to US16/448,069 priority patent/US11154534B2/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • the present invention relates to a lipid particle composition containing panobinostat or a salt thereof, and a pharmaceutical composition containing the lipid particle composition.
  • Panobinostat is a hydroxamic acid derivative used for the treatment of multiple myeloma and is one of non-selective histone deacetylase inhibitors. Panobinostat is marketed in the form of a capsule-type oral preparation under the trade name Faridac (registered trademark).
  • the liposome preparation is a preparation in which a drug is encapsulated in a liposome composed of a lipid membrane.
  • Non-Patent Document 1 describes a liposome preparation targeting bone marrow.
  • Non-Patent Document 1 includes 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), cholesterol, L-glutamic acid, N- (3-carboxyl-1-oxopropyl) -1,5-dihexa
  • DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
  • SA lipids decyl esters
  • poly ethylene glycol
  • Non-Patent Document 2 describes that a liposome encapsulating cytarabine and daunorubicin (CPX-351) exhibits high bone marrow accumulation.
  • Non-Patent Document 2 describes that accumulation of CPX-351 in the bone marrow is 20% to 50% higher in normal mice than empty liposomes and 75% higher in leukemia model mice than empty liposomes. Has been.
  • An object of the present invention is to provide a lipid particle composition containing panobinostat or a salt thereof and exhibiting high targeting ability to bone marrow, and a pharmaceutical composition containing the lipid particle composition.
  • lipid particle composition containing panobinostat or a salt thereof wherein the lipid particle composition containing phospholipids and cholesterols is a bone marrow.
  • the present invention has been completed.
  • a lipid particle composition comprising panobinostat or a salt thereof, wherein the lipid particles comprise phospholipids and cholesterols.
  • Formula 1 (Bone marrow concentration-area under time curve) / (Gastrointestinal concentration-area under time curve) [3] The lipid particle composition according to [1] or [2], wherein the lipid particles have an average particle diameter of 50 nm to 500 nm. [4] The lipid particle composition according to [1] to [3], wherein panobinostat or a salt thereof is encapsulated in lipid particles by a remote loading method. [5] The lipid particle composition according to any one of [1] to [4], wherein the solidified product of panobinostat or a salt thereof is present on at least a part of the surface and inside of the lipid particle.
  • the lipid particle composition according to [9] wherein the sphingophospholipid is sphingomyelin.
  • the lipid particle composition according to any one of [1] to [11], wherein the lipid particles are substantially free of polyethylene glycol lipid.
  • a pharmaceutical composition comprising the lipid particle composition according to any one of [1] to [15].
  • a method for treating a subject comprising administering to the subject the lipid particle composition according to any one of [1] to [17].
  • the lipid particle composition and the pharmaceutical composition of the present invention exhibit high targeting ability to bone marrow. According to the lipid particle composition and the pharmaceutical composition of the present invention, it is possible to provide a pharmaceutical composition having an improved therapeutic index.
  • FIG. 1 shows an image of a panobinostat-containing lipid particle obtained by a transmission electron microscope (Transmission Electron Microscope; TEM).
  • FIG. 2 shows the results of measurement of panobinostat concentration in plasma after administration of panobinostat-containing lipid particles or panobinostat solution.
  • FIG. 3 shows the results of measurement of panobinostat concentration in the tissue after administration of panobinostat-containing lipid particles or panobinostat solution.
  • FIG. 4 shows the results of measuring the growth inhibitory activity on leukemia cells in the Molm-13 orthotopic model mouse.
  • FIG. 5 shows the results of analyzing the number of macrophages in bone marrow and the amount of lipid particles in cells.
  • FIG. 6 shows the results of analyzing cytokine expression in bone marrow.
  • a numerical range indicated by using “to” indicates a range including the numerical values described before and after “to” as the minimum value and the maximum value, respectively.
  • the amount of each component in the composition means the total amount of the plurality of substances present in the composition unless there is a specific notice when there are a plurality of substances corresponding to each component in the composition. To do.
  • “Empty liposome” means a liposome containing no drug. “Release” means that a drug contained in a lipid particle (such as a liposome) passes through a lipid membrane constituting the lipid particle (such as a liposome) and exits from the lipid particle (such as a liposome). “Retention in the blood” means a property in which a drug encapsulated in lipid particles (such as liposomes) is present in blood in a subject administered with a composition of lipid particles (such as liposomes).
  • the average particle diameter of lipid particles (liposomes, etc.) means the volume average particle diameter of lipid particles (liposomes, etc.) present in the composition of lipid particles (liposomes, etc.).
  • the average particle diameter of the lipid particles contained in the lipid particle composition of the present invention is measured using a dynamic light scattering method. Examples of commercially available measuring apparatuses using dynamic light scattering include a dense particle analyzer FPAR-1000 (manufactured by Otsuka Electronics Co., Ltd.), Nanotrack UPA (manufactured by Nikkiso Co., Ltd.), and nanosizer (manufactured by Malvern).
  • Subject refers to mammals such as humans, mice, monkeys, and livestock that require prevention or treatment of diseases, and preferably humans that require prevention or treatment of diseases and the like.
  • the lipid particle composition of the present invention is a lipid particle composition containing panobinostat or a salt thereof, wherein the lipid particles contain phospholipids and cholesterols.
  • Lipid particles A lipid particle means the particle
  • Lipid particles of the present invention include liposomes having lamellar structures that are closed vesicles composed of lipid bilayers.
  • a liposome is a closed vesicle formed of a lipid bilayer membrane using lipid, and has an aqueous phase (inner aqueous phase) in the space of the closed vesicle.
  • the inner water phase includes water and the like.
  • Liposomes usually exist in a dispersed state in an aqueous solution outside the closed vesicles (outer aqueous phase).
  • Liposomes are single lamellae (also called single-layer lamellae or unilamellar, and double-layer membranes have a single structure), but they are multi-layer lamellae (also called multi-lamellar, which have a large number of onion-like bilayer membranes).
  • it is a single-lamellar liposome. Is preferred.
  • the lipid particles of the present invention also include particles that do not have a lipid bilayer structure (lamellar structure) like the above-mentioned liposome and that have a structure filled with constituent components inside the particle.
  • the form of lipid formation can be confirmed by electron microscope observation or structural analysis using X-rays.
  • lipid particles such as liposomes have a lipid bilayer structure (lamella structure) and an inner water layer, or lipid particles such as liposomes. Since it has a lipid bilayer structure (lamellar structure) and a core with high electron density inside the particle without an inner water layer, it is confirmed that it has a structure filled with components such as lipids. it can.
  • SAXS lipid X-ray scattering
  • the form of the lipid particle is not particularly limited as long as it is a lipid particle capable of encapsulating a drug.
  • Encapsulation means that the drug is in a form that is contained in the inner aqueous phase and / or the membrane itself with respect to the lipid particles.
  • a form in which a drug is enclosed in a closed space formed of a film, a form in which the drug is included in the film itself, and the like may be used.
  • the average particle size of the lipid particles is generally 10 nm to 1000 nm, preferably 50 nm to 500 nm, more preferably 100 nm to 500 nm, and further preferably 100 nm to 300 nm.
  • the lipid particles preferably have a spherical shape or a form close thereto.
  • the zeta potential of the lipid particles according to the present invention is not particularly limited, but is preferably ⁇ 10 mV or less, more preferably ⁇ 15 mV or less, further preferably ⁇ 20 mV or less, and may be ⁇ 25 mV or less. Preferably, it is more preferably ⁇ 30 mV or less.
  • the component constituting the lipid bilayer of the lipid particle is selected from lipids.
  • lipid any lipid that can be dissolved in a mixed solvent of a water-soluble organic solvent and an ester-based organic solvent can be arbitrarily used.
  • lipids include phospholipids, lipids other than phospholipids, cholesterols, lysophospholipids, and derivatives thereof. These components may be composed of a single type or multiple types of components.
  • the lipid particles in the present invention include at least phospholipids and cholesterols.
  • the phospholipid examples include phosphatidylcholine (lecithin), phosphatylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, dihydrosphingomyelin, cardiolipin, and hydrogen Added one (for example, hydrogenated soybean phosphatidylcholine (HSPC)) and the like.
  • the “phospholipid” includes phospholipid derivatives obtained by modifying phospholipids.
  • the phospholipid preferably includes a phospholipid having a glycerol skeleton.
  • phosphatidylcholine is particularly preferable.
  • phosphatidylcholine 1,2-dialacidonoyl-sn-glycero-3-phosphocholine and the like can be used.
  • sphingophospholipid As the sphingophospholipid, sphingomyelin and the like can be used.
  • the phospholipid in the present invention preferably contains a fatty acid residue having 20 or more carbon atoms from the viewpoint of reducing the release of panobinostat or a salt thereof and improving the blood retention.
  • lipids other than phospholipids include lipids that do not contain phosphoric acid, such as glycerolipids that do not have a phosphate moiety in the molecule, and sphingolipids that do not have a phosphate moiety in the molecule.
  • lipid other than phospholipid includes derivatives of lipids other than phospholipids obtained by modifying lipids other than phospholipids.
  • cholesterols examples include cholesterol having cyclopentahydrophenanthrene as a basic skeleton, and part or all of which are hydrogenated, and derivatives thereof.
  • An example is cholesterol.
  • the addition of cholesterol is expected to lower the fluidity of the lipid particle membrane by filling the gap in the lipid particle membrane.
  • the content of cholesterols relative to the total amount of lipid constituting the lipid particle according to the present invention is preferably 10 mol% to 50 mol%, more preferably 20 mol% to 45 mol%, further preferably 30 mol% to 45 mol%, and more preferably 35 mol% to 45 mol%. % Is particularly preferred.
  • the lipid particles in the present invention may contain a lipid modified with a hydrophilic polymer.
  • a hydrophilic polymer examples include polyethylene glycols, polyglycerins, polypropylene glycols, polyvinyl alcohol, styrene-maleic anhydride alternating copolymer, polyvinyl pyrrolidone, and synthetic polyamino acid. Said hydrophilic polymer can be used individually or in combination of 2 types or more, respectively.
  • polyethylene glycols, polyglycerols and polypropylene glycols are preferable from the viewpoint of blood retention of the composition, and polyethylene glycol (PEG), polyglycerol (PG) and polypropylene glycol (PPG) are more preferable. From the viewpoint of versatility and blood retention, polyethylene glycol (PEG) is more preferable.
  • the weight average molecular weight of polyethylene glycol is not particularly limited, but is 500 to 10,000 daltons, preferably 1,000 to 7,000 daltons, and more preferably 2,000 to 5,000 daltons.
  • lipid modified with PEG polyethylene glycol lipid
  • the polyethylene glycol lipid examples include 1,2-distearoyl-3-phosphatidylethanolamine-PEG2000 (manufactured by NOF Corporation), 1,2-distearoyl-3-phosphatidylethanolamine-PEG5000 (manufactured by NOF Corporation) and Examples include 1,2-distearoyl-3-phosphatidylethanolamine-polyethylene glycol such as distearoylglycerol-PEG2000 (manufactured by NOF Corporation).
  • the ratio of polyethylene glycol lipid in the total lipid constituting the lipid particle is generally 0.01 to 10 mol%, preferably 0.05 to 8 mol%, more preferably 0.1 to 7 mol%. %, Preferably 5 mol% or less, and more preferably 1 mol% or less.
  • the lipid particle does not substantially contain polyethylene glycol lipid.
  • the lipid particle in the present invention preferably contains an anionic lipid together with the main lipid contained in the lipid particle.
  • anionic lipids include phosphatidylglycerol-containing lipids such as 1,2-Dipalmitoyyl-sn-glycero-3-phosphoglycerol, sodium salt (COATSOME MG-6060LS, manufactured by NOF Corporation), and 1,2-Dimyristoyyl-sn.
  • phosphatidic acid such as glycero-3-phosphophatic acid, sodium salt (COATSOME MA-6060LS, manufactured by NOF Corporation), 1,2-Dipalmitylyl-sn-glycero-3-phospho-L-serine, sodiumCOSMET ME MS-6060LS (manufactured by NOF) and other phosphatidylserine-containing lipids, 1-Stearoy -2-Lyso-sn-glycero-3-phosphoricols such as phosphocholine (COTSOME MC-80H, NOF Corporation), steroid derivatives having an anionic group such as Cholesteryl hemisuccinate (CHEMS, manufactured by Avanti Polar Lipids), stearic acid And fatty acids.
  • COATSOME MA-6060LS manufactured by NOF Corporation
  • 1,2-Dipalmitylyl-sn-glycero-3-phospho-L-serine sodiumCOSMET ME MS-6060LS (manufactured by NOF) and
  • the ratio of the anionic lipid in the total lipid constituting the lipid particle is not particularly limited, but is 0.01 to 50 mol%, preferably 0.05 to 30 mol%, more preferably 0.1 to 10 mol%. Mol%.
  • Anionic lipids may be used in combination with PEG lipids, or PEG lipids may be used alone without being used.
  • said hydrophilic polymer can be used individually or in combination of 2 or more types, respectively.
  • the lipid particles are added with a hydrophilic polymer for improving the retention in blood, fatty acid or diacetyl phosphate as a membrane structure stabilizer, and ⁇ -tocopherol as an antioxidant. Also good.
  • additives such as dispersion aids that are not approved for intravenous use in pharmaceutical applications, such as surfactants.
  • Panobinostat The lipid particle composition of the present invention contains panobinostat or a salt thereof as a drug.
  • Panobinostat is a hydroxamic acid derivative used for the treatment of multiple myeloma and is one of non-selective histone deacetylase inhibitors. The chemical structure of panobinostat is shown below.
  • panobinostat examples include salts of basic groups such as amino groups that are generally known.
  • the salt in the basic group include salts with mineral acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, boric acid, nitric acid and sulfuric acid; formic acid, acetic acid, lactic acid, citric acid, oxalic acid, fumaric acid, malein Acids, succinic acid, malic acid, tartaric acid, aspartic acid, salts with organic carboxylic acids such as trichloroacetic acid and trifluoroacetic acid; and methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid and naphthalenesulfonic acid And salts with sulfonic acid such as As an example of the panobinostat salt, there may be mentioned panobinostat lactate, the structure of which is shown below.
  • panobinostat or salt thereof contained in the lipid particle composition In the lipid particle composition of the present invention, the presence state of panobinostat or a salt thereof in the lipid particle is not particularly limited, but at least of panobinostat or a salt thereof from the difference in accumulation in bone marrow with empty liposomes as described later. Some are presumed to exist in a form that affects recognition by cells such as proteins or macrophages in blood that recognize lipid particles. That is, it is presumed that panobinostat or a part of the salt thereof is present on the membrane surface of the lipid particle or in a state in which the mobility of lipid molecules existing on the membrane surface is affected.
  • panobinostat or a salt thereof contained in the lipid particle composition when panobinostat or a salt thereof contained in the lipid particle composition is in a high concentration, the presence state of panobinostat or a salt thereof is selected from among panobinostat or a salt thereof as can be read from the TEM image of FIG.
  • a part may exist as a solidified substance on at least a part of the surface and inside of the lipid particle. Even in such a case, the remainder of panobinostat or a salt thereof may exist in a dissolved state in the inner aqueous phase of the lipid particles.
  • the dissolved state is considered to be encapsulated in the dissolved state when the amount of the drug filled with respect to the volume of the lipid particles is equal to or lower than the saturated solubility of the drug in the composition solution of the inner aqueous phase.
  • the drug crystal is not observed with Cryo-TEM [observation of a frozen sample with a transmission electron microscope (TEM)] or the diffraction pattern due to the crystal lattice is not observed with XRD measurement, the lipid particles are not less than saturated solubility. It can be considered that most of the drug contained in the drug dissolves and exists in a dissolved state.
  • the solidified product means a solid that can be observed with a transmission electron microscope (TEM).
  • TEM transmission electron microscope
  • panobinostat or its salt / lipid ratio in the lipid particles is 10 to 500 mg / mmol, preferably 20 to 400 mg / mmol, more preferably 30 to 300 mg / mmol.
  • panobinostat salt is included, the panobinostat or its salt / lipid ratio is calculated by the amount converted to panobinostat.
  • the lipid in panobinostat or a salt / lipid ratio thereof means all lipids constituting the lipid particle, and the lipid includes cholesterol and lysophospholipid.
  • the area ratio represented by the following formula 1 is from 1 after a single dose of 4 mg / kg of the lipid particle composition as panobinostat to the tail vein of a mouse until infinite time. It is preferably large, more preferably 2 or more, still more preferably 3 or more, further preferably 5 or more, still more preferably 10 or more, and particularly preferably 12 or more.
  • Formula 1 (Bone marrow concentration-area under time curve) / (Gastrointestinal concentration-area under time curve)
  • the bone marrow accumulation rate (% ID / g) represented by the following formula 2 is preferably 10% ID / g or more, more preferably 15% ID / g or more. More preferably, it is 20% ID / g or more, More preferably, it is 30% ID / g or more, Especially preferably, it is 40% ID / g or more.
  • the bone marrow accumulation rate shown in the examples of the present invention is a panoinostat-containing lipid particle composition (panobinostat amount of 6 mg / kg) labeled with DiI (1,1′-dioctadecyl-3,3,3 ′, 3′-tetramethyllindocarbocyanine Perchlorate).
  • a label different from DiI used in the present invention may be used, or the lipid constituting the lipid particle is traced without using the label.
  • the bone marrow accumulation rate may be obtained by Further, in addition to the method of labeling the lipid particle composition in advance as shown in the examples of the present invention, the bone marrow accumulation rate using the method of labeling the lipid particle composition later as shown in Example 25. Can also be requested.
  • the lipid particle composition of the present invention can contain lipid particles containing panobinostat or a salt thereof and an aqueous solvent in which the lipid particles are dispersed.
  • the lipid particle composition of the present invention may contain at least one of pharmaceutically acceptable isotonic agents, stabilizers, antioxidants, and pH adjusters in relation to the administration route.
  • the isotonic agent is not particularly limited, but for example, inorganic salts such as sodium chloride, potassium chloride, sodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, glycerol, mannitol, sorbitol, etc.
  • inorganic salts such as sodium chloride, potassium chloride, sodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, glycerol, mannitol, sorbitol, etc.
  • examples include polyols, sugars such as glucose, fructose, lactose, or sucrose.
  • the stabilizer is not particularly limited, and examples thereof include saccharides such as glycerol, mannitol, sorbitol, lactose, or sucrose.
  • antioxidant For example, ascorbic acid, uric acid, a tocopherol homologue (For example, four isomers of vitamin E, tocopherol alpha, beta, gamma, and delta), cysteine, EDTA (ethylenediaminetetraacetic acid) Propyl gallate, BHT (dibutylhydroxytoluene), BHA (butylhydroxyanisole), sodium pyrosulfite and the like.
  • the stabilizer and the antioxidant can be used alone or in combination of two or more.
  • pH adjusters examples include sodium hydroxide, citric acid, acetic acid, triethanolamine, sodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, and the like.
  • the lipid particle composition of the present invention comprises a pharmaceutically acceptable organic solvent, collagen, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, sodium carboxymethylcellulose, sodium polyacrylate, sodium alginate, water-soluble dextran, sodium carboxymethyl starch Pectin, methylcellulose, ethylcellulose, xanthan gum, gum arabic, casein, gelatin, agar, diglycerin, propylene glycol, polyethylene glycol, petrolatum, paraffin, stearyl alcohol, stearic acid, human serum albumin (HSA), mannitol, sorbitol, lactose, Phosphate buffered saline (PBS), sodium chloride, saccharides, biodegradable polymer, serum-free medium, pharmaceutical additives It may contain acceptable additives as.
  • a pharmaceutically acceptable organic solvent collagen, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, sodium carboxy
  • the container filled with the lipid particle composition of the present invention is not particularly limited, but is preferably made of a material having low oxygen permeability.
  • gas barrier layer made of plastic container, glass container, aluminum foil, aluminum vapor deposition film, aluminum oxide vapor deposition film, silicon oxide vapor deposition film, polyvinyl alcohol, ethylene vinyl alcohol copolymer, polyethylene terephthalate, polyethylene naphthalate, polyvinylidene chloride, etc.
  • a back using a colored glass, an aluminum foil, an aluminum vapor-deposited film, or the like can be used to shield the light.
  • the container filled with the lipid particle composition it is preferable to replace the gas in the container space and the chemical solution with an inert gas such as nitrogen in order to prevent oxidation due to oxygen present in the space in the container.
  • an inert gas such as nitrogen
  • the injection solution may be bubbled with nitrogen and filled into a container under a nitrogen atmosphere.
  • lyophilization is also preferably performed.
  • the method for producing the lipid particle composition of the present invention is not particularly limited.
  • each component (phospholipid, cholesterol, etc.) constituting the lipid particles is mixed with an organic solvent, and the mixture is heated to dissolve the above components to produce the oil phase. can do.
  • organic solvent used in an oil phase is not specifically limited, For example, the water-soluble organic solvent arbitrarily mixed with water can be used.
  • water-soluble organic solvent examples include alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol and t-butanol, glycols such as glycerin, ethylene glycol and propylene glycol, and polyethylene glycol. Examples include polyalkylene glycols. Among these, alcohols are preferable.
  • the alcohol is preferably at least one selected from ethanol, methanol, 2-propanol and t-butanol, more preferably at least one selected from ethanol, 2-propanol and t-butanol, More preferably, it is ethanol.
  • the lipid concentration is not particularly limited and can be appropriately adjusted.
  • aqueous phase water (distilled water, water for injection, etc.), physiological saline, various buffer solutions or aqueous solutions of saccharides, and a mixture thereof (aqueous solvent) can be used.
  • aqueous solvent aqueous solvent
  • panobinostat is encapsulated in lipid particles by remote loading described later, it is preferable to use an aqueous solution containing an ammonium salt as the aqueous phase.
  • the buffer is not limited to organic or inorganic, but a buffer having a buffering action near the hydrogen ion concentration close to the body fluid is preferably used.
  • Phosphate buffer, Tris buffer, citric acid Examples include a buffer solution, an acetate buffer solution, and a good buffer.
  • the inner aqueous phase of the lipid particles may be an aqueous solution in which the lipid particles are dispersed when the lipid particles are produced, or newly added water, physiological saline, various buffer solutions or aqueous solutions of saccharides and these. It may be a mixture of It is preferable that the water used as the outer aqueous phase or the inner aqueous phase does not contain impurities (dust, chemical substances, etc.).
  • Physiological saline means an inorganic salt solution adjusted to be isotonic with the human body, and may further have a buffering function.
  • physiological saline examples include saline containing 0.9 w / v% (mass / volume percent) of sodium chloride, PBS, and Tris buffered physiological saline.
  • the aqueous phase includes both an outer aqueous phase and an inner aqueous phase.
  • the outer aqueous phase in the present invention means an aqueous solution in which lipid particles are dispersed.
  • the solution occupying the outside of the lipid particles in the dispersion of lipid particles stored in a vial or prefilled syringe package is the outer aqueous phase.
  • the liquid occupying the outer side of the lipid particles in the lipid particle dispersion is the outer aqueous phase of the liquid dispersed at the time of administration using the attached dispersion liquid or other solution.
  • the inner aqueous phase in the present invention means an aqueous phase in a closed vesicle separated by a lipid bilayer of lipid particles.
  • ⁇ (C) Lipid particle formation by emulsification In the emulsification step, an oil phase in which at least one kind of lipid is dissolved in an organic solvent and an aqueous phase are mixed, and an aqueous solution containing the lipid can be stirred and emulsified.
  • an emulsion in which the oil phase and the aqueous phase are emulsified in the O / W type (oil-in-water type) is prepared.
  • lipid particles are formed by removing part or all of the organic solvent derived from the oil phase by evaporation. Alternatively, part or all of the organic solvent in the oil phase evaporates in the course of stirring and emulsification to form lipid particles.
  • ultrasonic waves or mechanical shearing force is used for particle refinement.
  • an extruder process or a microfluidizer process through a filter having a fixed pore diameter can be performed. If an extruder or the like is used, the secondary vesicle lipid particles can be separated into single vesicle lipid particles.
  • the emulsification step is not limited as long as it is an emulsification step, but is preferably a step in which high shear is applied and fine particles are formed in an emulsification step including an organic solvent. If necessary, lipid particles can be formed by evaporating (desolving) the organic solvent used in the emulsification step.
  • the liquid temperature in the emulsification step when producing the lipid particles can be adjusted as appropriate, but the liquid temperature during mixing of the oil phase and the aqueous phase is preferably equal to or higher than the phase transition temperature of the lipid used.
  • the temperature is preferably 35 ° C. to 70 ° C.
  • the organic solvent and water may be evaporated from the aqueous solution containing lipid particles.
  • the term “evaporation” as used herein may forcibly remove part or all of the organic solvent derived from the oil phase and the water derived from the aqueous phase as an evaporation step, or the organic solvent derived from the oil phase and the water derived from the aqueous phase. A part or all of these may naturally evaporate in the process of stirring and emulsification.
  • the method of evaporation is not particularly limited. For example, at least one of a step of evaporating by heating an organic solvent and water, a step of standing still or gently stirring after emulsification, and a step of performing vacuum deaeration is performed. Just do it.
  • the obtained lipid particles can have a uniform particle size using a dialysis method, a filtration method or an extrusion treatment.
  • the extrusion treatment means a process of applying physical shearing force and atomizing by passing lipid particles through a filter having pores.
  • the lipid particle dispersion liquid and the filter can be rapidly atomized by maintaining the temperature at a temperature equal to or higher than the phase transition temperature of the membrane constituting the lipid particles.
  • the sizing by the extruder may or may not be performed.
  • the lipid particle outer aqueous phase liquid may be replaced by dialysis.
  • the dialysate a 0.1 to 5% by mass NaCl aqueous solution can be used, but is not particularly limited.
  • panobinostat is preferably encapsulated in lipid particles by a remote loading method.
  • the remote loading method means a method of producing an empty liposome in which no drug is encapsulated and introducing the drug into the liposome by adding the drug to the liposome external solution.
  • the remote loading method is not particularly limited, and examples thereof include a method using a citrate buffer or ammonium sulfate.
  • the drug added to the external liquid is actively transferred to the lipid particles and taken into the lipid particles.
  • a solubility gradient, an ion gradient, a pH gradient, or the like is used as the driving force.
  • a solubility gradient, an ion gradient, a pH gradient, or the like is used.
  • there is a method of introducing a drug into lipid particles using an ion gradient formed across a lipid particle membrane for example, there is a technique in which a drug is added to lipid particles formed in advance by a remote loading method using a Na + / K + concentration gradient.
  • a proton concentration gradient is generally used.
  • the inside (inner aqueous phase) pH of the lipid particle membrane has a lower pH gradient than the outer (outer aqueous phase) pH.
  • the pH gradient can be formed by an ammonium ion gradient and / or a concentration gradient of an organic compound having an amino group that can be protonated.
  • the source of ammonium ions is not particularly limited, but a water-soluble ammonium salt is preferably used, and examples thereof include ammonium sulfate, ammonium chloride, ammonium formate, ammonium succinate, and ammonium acetate.
  • the lipid particle solution encapsulating panobinostat may be dialyzed to remove panobinostat not contained in the lipid particles. For example, using a sucrose / histidine buffer at a predetermined concentration as a dialysis solution, dialysis is performed on a lipid particle solution encapsulating panobinostat to remove panobinostat present in the outer aqueous phase, and the dialysis solution is used to remove the outer aqueous phase. Can be obtained.
  • the lipid particle composition obtained above is preferably subjected to aseptic filtration.
  • As a filtration method an unnecessary thing can be removed from the aqueous solution containing lipid particles using a hollow fiber membrane, a reverse osmosis membrane, a membrane filter, or the like.
  • the aseptic filtration step and the aseptic filling step described later are preferably performed at a temperature lower than the phase transition temperature of the lipid constituting the lipid particles.
  • the lipid phase transition temperature is around 50 ° C., it is preferably about 0 to 40 ° C., and more specifically, it is preferably produced at about 5 to 30 ° C.
  • the lipid particle composition obtained after aseptic filtration is preferably aseptically filled for medical use.
  • a known method can be applied for aseptic filling.
  • a lipid particle composition suitable for medical use can be prepared by filling the container aseptically.
  • the lipid particle composition of the present invention can be used as a pharmaceutical composition. That is, according to the present invention, a pharmaceutical composition comprising the lipid particle composition of the present invention is provided.
  • parenteral administration is preferable.
  • intravenous injection such as infusion, intramuscular injection, intraperitoneal injection, subcutaneous injection, intraocular injection, and intrathecal injection
  • administration method include administration by syringe or infusion.
  • the dose and frequency of administration of panobinostat or a salt thereof as a drug contained in the lipid particle composition are generally in the range of 0.01 mg / kg to 100 mg / kg per day as the mass of panobinostat or a salt thereof. Although it can set, the lipid particle composition of this invention is not limited to these dosages.
  • the pharmaceutical composition of the present invention can be preferably used as an anticancer agent.
  • the type of cancer to which the pharmaceutical composition of the present invention is applied is not particularly limited.
  • DiI 1,1′-dioctadecyl-3,3,3 ′, 3′-tetramethyllindocarbocyneine perchlorate
  • a quantity of DiI corresponding to 0.2 mol% with respect to the total lipid is weighed and added to ethanol. Dissolved. Ethanol was added to the DiI ethanol solution to a total volume of 11.25 mL, and 3.75 mL of ethyl acetate was further added. The weighed lipid and this organic solvent were mixed and heated to 60 ° C. to dissolve the lipid to obtain an oil phase.
  • (C) Lipid particle formation by emulsification After heating the aqueous phase prepared in (b) to 70 ° C. and adding the total amount of oil phase prepared in (a) (volume ratio: aqueous phase / oil phase 8/3) ) And an emulsifier (Excel Auto Homogenizer ED-3, manufactured by Nippon Seiki Seisakusho) at 3000 rpm (rotation per minute: 1/60 s ⁇ 1 ) for 30 minutes. Subsequently, stirring was continued at 300 rpm while heating at 65 ° C. to evaporate the organic solvent and water. When the liquid was concentrated to 15 g, heating and stirring were stopped, and evaporation was stopped.
  • Example 1 Size adjustment using an extruder
  • particle size adjustment is not performed, but among the examples described in the following table, the filter size is described in the column of “size adjustment” as follows.
  • the sizing was carried out. Using an extruder (Mini Extruder, manufactured by Avanti Polar Lipids) under heating at 70 ° C., the liquid obtained in (c) was passed through a filter in order to adjust the size. As the size of the filter, the one described in the “Sizing” column of each table was used. In Examples where a plurality of filter sizes were described, the particles were sized using a filter having a large pore size, and then sized using a filter having a small pore size.
  • panobinostat APAC PHARMACEUTICAL, LLC
  • panobinostat APAC PHARMACEUTICAL, LLC
  • 8 mol / L HCl solution was added while thoroughly stirring the solution, and the pH was adjusted to about 3 to dissolve panobinostat.
  • Lipid particles were added to this panobinostat solution at a volume ratio of 1/1, and then heated at 60 ° C. for 120 minutes.
  • Example 2 Panobinostat-containing lipid particles were obtained in the same manner as in Example 1 except that the amount of DSPE-PEG used was 0.0153 g.
  • SM represents Sphingomyelin (COATSOME NM-10, manufactured by NOF Corporation)
  • DHSM Dihydrosphingomyelin (a synthetic product obtained by hydrogenation of COATSOME NM-10 (manufactured by NOF Corporation)).
  • panobinostat (APAC PHARMACEUTICAL, LLC) to make 4 mg / mL. Further, 8 mol / L HCl solution was added while thoroughly stirring the solution, and the pH was adjusted to about 4 to dissolve panobinostat.
  • the panobinostat solution, 720 mM NaCl aqueous solution, and lipid particles were mixed at a volume ratio of 5/3/2, and then heated at 60 ° C. for 120 minutes.
  • Example 15 to 25 Panobinostat-containing lipid particles were obtained in the same manner as in Example 14 with the lipid compositions described in Tables 2-4. In Example 25, lipid particles were prepared without adding DiI.
  • C20PC is 1,2-dialacidonoyl-sn-glycero-3-phosphocholine (manufactured by Nippon Seika)
  • HSPC hydrogenated soybean phosphatidylcholine (COATSOME NC-21, NOF Corporation)
  • DPPG is 1 , 2-Dipalmitoyyl-sn-glycero-3-phosphosylcerol, sodium salt (COATSOME MG-6060LS, manufactured by NOF Corporation)
  • DPPA is 1,2-Dimyristoyyl-sn-glycosidic-3-acids 6060LS (manufactured by NOF Corporation)
  • DPPS is 1,2-Dipalmitoyyl-sn-glycero-3-phospho-L-ser ne,
  • panobinostat solution was 3.6 mg / mL.
  • the mixing ratio of panobinostat solution, 720 mM NaCl aqueous solution and lipid particles was 8/5/5 in Example 16 and 2/1/1 in Examples 17-25.
  • Example 22 Only in Example 22, the average particle size is 331 nm, which is larger than others. This is because the average particle diameter was greatly calculated because the peak of aggregates was observed in the vicinity of 1 ⁇ m in the particle diameter measurement by DLS. In Example 22, the absolute value of the zeta potential is small, and the electrostatic repulsion between particles is small. Also, a material such as DSPE-PEG that prevents the particles from coalescing due to steric repulsion is not added. Although the bone marrow accumulation rate is high, it can be said that the other examples are more preferable from the viewpoint of particle stability.
  • Example 25 In Example 25, (I) DiI was not added at the time of preparation of the oil phase, and staining with DiI was performed on lipid particles that had been subjected to dialysis with a sucrose / histidine buffer in (g). After mixing 5 ⁇ L of 3 mg / mL DiI / ethanol solution with 500 ⁇ L of lipid particle solution and stirring well, the outer aqueous phase is 9.4% by mass by gel filtration (PD MiniTrap G-25, manufactured by GE Healthcare). Substitution was carried out with a sucrose / histidine buffer consisting of sucrose and 10 mmol / L histidine to remove excess DiI.
  • a sucrose / histidine buffer consisting of sucrose and 10 mmol / L histidine to remove excess DiI.
  • Panobinostat was dissolved in a 1: 4 volume ratio mixture of polyoxyl 35 castor oil (Kolliphore EL, manufactured by SIGMA) and polyethylene glycol 400 (manufactured by Wako Pure Chemical Industries, Ltd.) while irradiating with ultrasonic waves.
  • the obtained solution and physiological saline were mixed at a volume ratio of 1: 7 to obtain a 0.5 mg / mL panobinostat solution.
  • HSPC, cholesterol, and DSPE-PEG were weighed 16.63 g, 2.04 g, and 4.15 g, respectively, together with DiI in an amount of 0.2 mol% based on the total lipid, and 303.75 mL of ethanol and 101.25 mL of ethyl acetate.
  • a water phase was prepared by mixing 5.6 g of 100 mmol / L sodium dihydrogen phosphate, 37.6 g of 100 mmol / L disodium hydrogen phosphate, and 1037 g of water for injection.
  • the oil phase was mixed with the aqueous phase, and empty liposomes labeled with DiI were prepared using an emulsification method.
  • the outer aqueous phase was replaced with TFF using 0.09 mass% sodium chloride aqueous solution, and then pemetrexed was encapsulated by the passive loading method.
  • Dialysis was performed with a sucrose / histidine buffer composed of 9.4% by mass sucrose and 0.155% by mass histidine to obtain lipid particles containing pemetrexed.
  • HSPC, cholesterol, and DSPE-PEG were weighed 12.42 g, 4.14 g, and 4.14 g, respectively, and 303.4 mL of ethanol and 101.25 mL of ethyl acetate together with an amount of DiI corresponding to 0.2 mol% with respect to the total lipid.
  • To give an oil phase 26.73 g of ammonium sulfate was dissolved in 1080 g of MilliQ water to obtain an aqueous phase.
  • liposomes empty liposomes labeled with DiI containing ammonium sulfate were prepared.
  • doxorubicin hydrochloride was encapsulated by a remote loading method. Dialysis was performed with a sucrose / histidine buffer composed of 9.4% by mass sucrose and 0.155% by mass histidine to obtain lipid particles containing doxorubicin hydrochloride.
  • the composition of the lipid particles was based on the composition described in the package insert of doxil injection 20 mg (doxorubicin hydrochloride 2 mg / mL, HSPC 9.58 mg / mL, DSPE-PEG 3.19 mg / mL, cholesterol 3.19 mg / mL).
  • doxorubicin hydrochloride 2.24 mg / mL, HSPC 11.5 mg / mL, DSPE-PEG 4.1 mg / mL, and cholesterol 4.2 mg / mL.
  • the particle size means a cumulant average particle size measured by a dynamic light scattering method.
  • the average particle size of the examples and comparative examples described in each table is a cumulant average particle size measured by a dynamic light scattering method using a dense particle size analyzer FPAR-1000AS (manufactured by Otsuka Electronics Co., Ltd.) with an autosampler. The measurement results are shown in each table.
  • the zeta potential means a value measured by a laser Doppler method.
  • the zeta potential of the examples described in each table was obtained by diluting the lipid particle solution 20-fold with a sucrose / histidine buffer composed of 9.4% by mass sucrose and 10 mmol / L histidine as in the outer aqueous phase. It is a value measured by a measurement system ELSZ-2 (manufactured by Otsuka Electronics Co., Ltd.). The measurement results are shown in each table.
  • the API concentration described in each table is a value obtained by measuring the amount of panobinostat (free body) contained in the lipid particles by HPLC (high performance liquid chromatography). For detection of panobinostat, ultraviolet light (UV) of 279 nm was used.
  • UV ultraviolet light
  • the lipid concentration described in each table is the total concentration of each lipid obtained by quantifying each lipid contained in the lipid particles by HPLC (high performance liquid chromatography).
  • HPLC high performance liquid chromatography
  • a corona charged particle detector Corona CAD (charged aerosol detector) was used for lipid detection.
  • Example 1 lipid particle composition of Example 1 was snap-frozen and observed under cryo conditions using a general-purpose TEM to obtain a TEM image. The obtained TEM image is shown in FIG. From the TEM image in FIG. 1, it can be seen that the solidified panobinostat is present on at least a part of the surface and inside of the lipid particles.
  • panobinostat-containing lipid particles prepared in Examples 1 and 3 to 7 labeled with a fluorescent dye (DiI) were administered from the tail vein.
  • panobinostat-containing lipid particles prepared in Examples 2 and 8 to 13 labeled with a fluorescent dye (DiI) were administered from the tail vein.
  • lipid particles not containing panobinostat prepared in Comparative Example 2 labeled with a fluorescent dye (DiI) (the same amount as that of Example 1 as lipid amount) were administered from the tail vein.
  • lipid particles containing pemetrexed prepared in Comparative Example 3 labeled with a fluorescent dye (DiI) (1.5 mg / kg as a drug amount) were administered from the tail vein.
  • lipid particles (drug 16.7 mg / kg) containing doxorubicin hydrochloride prepared in Comparative Example 4 labeled with a fluorescent dye (DiI) were administered from the tail vein.
  • the collected bone marrow was quantified with the HPLC (High Performance Liquid Chromatography) fluorescence detector to determine the concentration of DiI in the administration solution and tissue, and the bone marrow accumulation rate was calculated by the following formula 2.
  • the bone marrow accumulation rate was shown by the ratio (% injected dose / g) (also expressed as% ID / g) of lipid particles administered per 1 g of bone marrow accumulated in the bone marrow. The measurement results are shown in each table.
  • the lipid particle compositions of Examples 1 to 25 of the present invention showed high bone marrow accumulation.
  • the lipid particles encapsulating panobinostat are presumed to be highly accumulated in the bone marrow by being recognized by macrophages as shown in the following analysis. All of the above factors are thought to contribute to indirectly enhancing the ability to accumulate bone marrow by affecting the ease of recognition by macrophages. For example, when the zeta potential is lowered by the addition of an anionic lipid, there is an effect that it is easily recognized by the scavenger receptor of macrophages, and this is considered to lead to an improvement in bone marrow accumulation.
  • Panobinostat-containing lipid particles (4 mg / kg as the drug amount) prepared in Examples 1, 2, 14 and 19 were administered to ICR mice (male, 7 weeks old) from the tail vein.
  • the panobinostat solution (5 mg / kg) prepared in Comparative Example 1 was intraperitoneally administered to ICR mice (male, 7 weeks old).
  • the dose of the panobinostat-containing lipid particles prepared in Examples 1, 2, 14 and 19 is set to the maximum tolerated dose in a single dose, and administration of the panobinostat solution prepared in Comparative Example 1 The amount was set to the maximum tolerated dose for daily administration for 8 days.
  • mice administered with the panobinostat-containing lipid particles prepared in Examples 1, 2, 14, and 19 were dissected at 3, 6, 24, 72, and 168 hours after administration.
  • Mice administered with the panobinostat solution prepared in Comparative Example 1 were dissected at 1, 3, 6, 24, and 72 hours after administration, and blood, femur bone marrow, and gastrointestinal tract (lower ileum) were collected.
  • the blood was centrifuged at 800 ⁇ g for 10 minutes, and plasma was collected.
  • the digestive tract was homogenized by freeze crushing.
  • the collected plasma, bone marrow and gastrointestinal tract were quantified for panobinostat concentration in tissues using liquid chromatography / mass spectrometry / mass spectrometry (LC / MS / MS).
  • the area under the tissue concentration-time curve (AUC) up to an infinite time after a single administration was calculated from the obtained tissue panofinostat concentration transition using the pharmacokinetic analysis software WinNonlin (registered trademark) (Certara). Further, the bone marrow / gastrointestinal tract ratio of AUC in the tissue was calculated from the following formula 1. The results are shown in FIGS. 2 and 3 and Table 5.
  • Pemetrexed-containing lipid particles 1.5 mg / kg as the drug amount
  • ICR mice male, 7 weeks old
  • mice administered with pemetrexed-containing lipid particles prepared in Comparative Example 3 were dissected 24, 72, 120, and 168 hours after administration, and blood, femur bone marrow, and digestive tract (lower ileum) were collected.
  • the tissue pemetrexed concentration was quantified in the same manner as panobinostat, and the bone marrow / gastrointestinal tract ratio of AUC and tissue AUC was calculated. The results are shown in Table 5.
  • panobinostat-containing lipid particles prepared in Examples 1, 2, 14 and 19 Panobinostat AUC showed a high bone marrow / gastrointestinal ratio and good bone marrow accumulation.
  • Panobinostat-containing lipid particles prepared in Example 1 from the 8th day after transplantation drug amount 8 mg / kg, tail vein administration, single administration
  • panobinostat solution prepared in Comparative Example 1 (5 mg / kg, intraperitoneal administration) , 8 days of continuous administration)
  • lipid particles containing no panoinostat prepared in Comparative Example 2 as a negative control the amount of lipid corresponding to 8 mg / kg of panoinostat-containing lipid particles prepared in Example 1; Administration was started.
  • the group which does not implement immunosuppression and a transplant as a non-transplant group was set. Mice were dissected 16 days after transplantation (8 days after the start of administration), and femur bone marrow was collected.
  • the obtained bone marrow was treated with a hemolysis buffer to remove erythrocytes, and then stained with a PerCP-labeled anti-human CD45 antibody and DAPI (4,6-diamidino-2-phenyllinole).
  • PerCP shows peridinin chlorophyll (Peridininchlorophyll).
  • flow cytometry the proportion of leukemia cells (human CD45 positive, DAPI negative cells) in living bone marrow was measured, and the growth inhibitory activity on leukemia cells in the Molm-13 orthotopic model mouse was compared. The measurement results are shown in FIG.
  • panobinostat-containing lipid particles prepared in Example 1 are higher in leukemia cell growth inhibition than the panobinostat solution prepared in Comparative Example 1 and the lipid particles not containing panobinostat prepared in Comparative Example 2. It was shown to be active and its effect was dose dependent.
  • Panobinostat-containing lipid particles prepared in Example 2 and labeled with DiI were administered to ICR mice (male, 7 weeks old) from the tail vein as a drug amount.
  • Non-administered, 6 hours after administration, and 96 hours after administration mice were dissected and femur bone marrow was collected.
  • the obtained bone marrow was treated with a hemolysis buffer to remove erythrocytes, and then stained with Alexa fluor (registered trademark) 647-labeled anti-mouse F4 / 80 antibody, FITC-labeled anti-mouse CD11b antibody, and DAPI.
  • Alexa fluor registered trademark
  • FITC fluorescein isothiocyanate.
  • flow cytometry the proportion of macrophages (mouse F4 / 80 positive, mouse CD11 positive, DAPI negative cells) in living bone marrow was measured. Furthermore, the amount of lipid particles taken into the cells was analyzed for a sample 96 hours after administration using the fluorescence intensity of intracellular DiI as an index. The analysis results are shown in FIG. In FIG. 5, M ⁇ indicates a macrophage.
  • the number of macrophages in the bone marrow increases with the lapse of time after administration of the panobinostat-containing lipid particles prepared in Example 2, and the panobinostat-containing lipid particles are taken into the increased macrophages. I understood.
  • the obtained bone marrow supernatant was subjected to protein concentration measurement by the BCA method (Bicinchonic Acid method), and each sample was diluted to a protein concentration of 8 mg / mL.
  • Cytokine concentrations in each sample were quantified using the Bio-Plex mouse cytokine GI23-Plex panel and the Bio-Plex200 system (Bio-Rad). The relative expression level change when the average value of cytokine expression level in non-administration was set to 1 was shown. The analysis results are shown in FIG.
  • IL indicates interleukin
  • G-CSF indicates granulocyte colony stimulating factor
  • GM-CSF indicates granulocyte monocyte colony stimulating factor
  • IFN indicates interferon
  • KC indicates keratinocyte chemoattractant
  • MCP stands for Monocytic Chemical Protein
  • MIP stands for Macrophage infraprotein protein
  • PANTES stands for regulated on activation normal T expressed and dead
  • TNF indicates tumor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2017/046564 2016-12-26 2017-12-26 脂質粒子組成物および医薬組成物 WO2018124033A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN201780080668.3A CN110114068A (zh) 2016-12-26 2017-12-26 脂质粒子组合物及医药组合物
ES17888488T ES2968358T3 (es) 2016-12-26 2017-12-26 Composición de partículas lipídicas y composición farmacéutica
JP2018559499A JPWO2018124033A1 (ja) 2016-12-26 2017-12-26 脂質粒子組成物および医薬組成物
EP17888488.8A EP3560492B1 (en) 2016-12-26 2017-12-26 Lipid particle composition and pharmaceutical composition
US16/448,069 US11154534B2 (en) 2016-12-26 2019-06-21 Lipid particle composition and pharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016250826 2016-12-26
JP2016-250826 2016-12-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/448,069 Continuation US11154534B2 (en) 2016-12-26 2019-06-21 Lipid particle composition and pharmaceutical composition

Publications (1)

Publication Number Publication Date
WO2018124033A1 true WO2018124033A1 (ja) 2018-07-05

Family

ID=62709478

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/046564 WO2018124033A1 (ja) 2016-12-26 2017-12-26 脂質粒子組成物および医薬組成物

Country Status (6)

Country Link
US (1) US11154534B2 (zh)
EP (1) EP3560492B1 (zh)
JP (4) JPWO2018124033A1 (zh)
CN (1) CN110114068A (zh)
ES (1) ES2968358T3 (zh)
WO (1) WO2018124033A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024215850A1 (en) * 2023-04-13 2024-10-17 W. L. Gore & Associates, Inc. Asymmetric membranes for nanoporous membrane extrusion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014121211A2 (en) * 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into liposomes
WO2017167837A1 (en) * 2016-03-31 2017-10-05 Midatech Ltd. Cyclodextrin-panobinostat adduct

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US9603800B2 (en) * 2012-04-12 2017-03-28 Yale University Methods of treating inflammatory and autoimmune diseases and disorders using nanolipogels
US20150209281A1 (en) * 2012-07-18 2015-07-30 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
CA2962709C (en) * 2014-08-04 2023-09-19 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into lipid vesicles
WO2016191363A1 (en) * 2015-05-22 2016-12-01 Aphios Corporation Combination hiv therapeutic
CN105457038A (zh) * 2015-11-09 2016-04-06 东南大学 一种速释型药物磷脂化合物及其药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014121211A2 (en) * 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into liposomes
WO2017167837A1 (en) * 2016-03-31 2017-10-05 Midatech Ltd. Cyclodextrin-panobinostat adduct

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Package Insert (1st ed.)", article "Farydak (R) Capsules", pages: 1 - 9 *
CHEN, H. ET AL.: "Development of Histone Deactylation Enzyme Inhibitor-containing Ribosomes for Cancer treatment Purposes (non-official translation)", ABSTRACTS OF THE 137TH ANNUAL MEETING OF THE PHARMACEUTICAL SOCIETY OF JAPAN:4, vol. 137, no. 4, 5 March 2017 (2017-03-05), pages 91, XP009516432, ISSN: 0918-9823 *
FUKAYA, NATSUKI ET AL.: "Development and Cancer Treatment Applications of Histone Deacetylation Enzyme Inhibitor-containing Ribosomes. (non-official translation)", ABSTRACTS OF THE 136TH ANNUAL MEETING OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 136, March 2016 (2016-03-01), pages 68, XP009516433 *
KALUSHKOVA, A.: "Polycomb Target Genes Are Silenced in Multiple Myeloma", PLOS ONE, vol. 5, no. 7, 9 July 2010 (2010-07-09), pages 1 - 12, XP055051149 *
KEITARO SOU ET AL., EXPERT OPIN DRUG DELIV., vol. 8, no. 3, March 2011 (2011-03-01), pages 317 - 328
SHARON A. JOHNSTONESHERWIN XIETROY HARASYMLAWRENCE MAYERPAUL GTARDI, PROCEEDINGS: AACR 101ST ANNUAL MEETING , 15 April 2010 (2010-04-15)

Also Published As

Publication number Publication date
JP2021073301A (ja) 2021-05-13
ES2968358T3 (es) 2024-05-09
EP3560492B1 (en) 2023-11-29
US11154534B2 (en) 2021-10-26
JP2022088508A (ja) 2022-06-14
CN110114068A (zh) 2019-08-09
JPWO2018124033A1 (ja) 2019-11-14
JP7343643B2 (ja) 2023-09-12
EP3560492A1 (en) 2019-10-30
EP3560492A4 (en) 2020-06-17
EP3560492C0 (en) 2023-11-29
US20190314335A1 (en) 2019-10-17
JP2023139213A (ja) 2023-10-03

Similar Documents

Publication Publication Date Title
JP7278436B2 (ja) リポソーム組成物および医薬組成物
JP6263609B2 (ja) リポソーム組成物及びその製造方法
WO2017078008A1 (ja) ゲムシタビンリポソーム組成物を含む腫瘍治療剤およびキット
US11684575B2 (en) Liposome composition and method for producing same
JPWO2015166987A1 (ja) リポソーム組成物及びその製造方法
JP7343643B2 (ja) 脂質粒子組成物および医薬組成物
JP6705933B2 (ja) リポソーム組成物およびその製造方法
JP2020079303A (ja) リポソーム及びリポソーム組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17888488

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2018559499

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2017888488

Country of ref document: EP